Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation: Prevalence, Risk Factors, And Outcomes  by Au, B.K.C. et al.
Oral PresentationsALLOGENEIC TRANSPLANTS7
BRONCHIOLITIS OBLITERANS SYNDROME FOLLOWING ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION: PREVALENCE, RISK FAC-
TORS, AND OUTCOMES
Au, B.K.C., Au, M.A., Chien, J.W. Fred Hutchinson Cancer Research
Center, Seattle, WA
We conducted a retrospective cohort study of the prevalence, risk
factors and outcomes of bronchiolitis obliterans syndrome (BOS),
a serious late pulmonary complication of allogeneic hematopoietic
cell transplantation (aHCT).
Methods: Pulmonary function tests (PFTs) from 1145 patients who
received their first aHCT between January 1, 2002 and June 30,
2006 were screened at$ 1 year after aHCT to identify patients who
met the NIH spirometry criteria for BOS (FEV1# 75% and FEV1/
VC ratio\0.7) and had a$ 10% decline in FEV1 compared to pre-
transplant values. Clinical, microbiologic, and radiologic records
were reviewed to exclude pulmonary infection and other causes of air-
flow obstruction as well as record supportive evidence for BOS.
Results: The overall prevalence of BOS among all transplanted pa-
tients was 5.5%. The prevalence of BOS among patients with chronic
graft-versus-host disease (cGVHD) and patients surviving to at least 1
year were 16% and 10%, respectively. The median time from trans-
plant to meeting spirometric criteria for BOS was 439 days (range
274-1690). 60% of the 63 total cases were clinically recognized at
the time of meeting NIH criteria, 23% were recognized
aftermeetingNIHcriteria, and 17%were never clinically recognized.
At the time of meeting NIH spirometric criteria, 95% of cases had
concurrent evidence of air trapping onPFTs (n5 58) and/or support-
ive evidence of BOS on high-resolution chest CT (n5 25). BOS was
significantly associated with cGVHD (p\0.001), low baseline FEV1
(p5 0.035), and low baseline FEV1/VC ratio (p5 0.001), but not
with other previously identified risk factors such as busulfan-based
regimen, peripheral blood stem cell source, donor-recipient gender
mismatch, or acuteGVHD. 48%of BOSpatients were on an immune
taper within 3months prior tomeetingNIH criteria. Survival analysis
revealed a significant difference inKaplanMeier survival estimates be-
tween subjects with and without BOS (p5 0.002). Non-relapse sur-
vival differed significantly based on clinical recognition status at the
time of meeting spirometric criteria (p5 0.027), with concurrently-
recognized patients having the worst survival.
Conclusion:These results suggest that BOSmay be more prevalent
than previously thought. Frequent assessment of high-risk patients
with cGVHD may help with earlier detection and intervention for
this often-fatal disease.8
PROSPECTIVE COMPARISON OF REDUCED INTENSITY (FLU-BU-ATG) VS.
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We prospectively compare 2 RIC: FBA (Fluda (150 mg/m2)+Oral
Bu (8 mg/kg) +Thymoglobuline (2.5 mg/kg)) (IS: CSA) or FTBI
(Fluda (90 mg/m2)+2 Gy TBI) (IS: CSA +MMF). Inclusion criteria:
hematological malignancies, pts non eligible for myeloablative CDT,
age between 18 and 65, HLA identical sibling. Groups (FBA:
N5 69; FTBI: N5 70) were comparable: age 54 (21-65); Male:
65%; Diag: AL 18%; NHL 23%; MM 39% others 20%; status: CR:
32%; SD5 60%; REF5 8%). Graft failure occured in 4 pts (6%) in
FTBI. Cumulative incidences (CI) of grade .5 2 aGVHD andcGVHD were respectively: 37% (FBA 51%; FTBI 26%; p5 .003)
and 77% (FBA 79%; FTBI 76%: p5NS). At 1 year, PFS differed
(FBA 0.68 [0.56 – 0.78]; FTBI 0.51 [0.39 – 0.62]; p5 0.048) while
OS was similar (FBA 0.75 [0.63 – 0.84]; FTBI 0.74 [0.62 – 0.83];
p5NS). With a f.up of 39 months (3-71), 72 pts were alive (FBA:
35; FTBI: 37: p5NS) for a 5 year probability of 0.45 [0.31– 0.57]
and 0.49 [0.35– 0.61] for FBA and FTBI respectively (p5NS). 5
year PFS probability were 0.35 [0.22– 0.48] for FBA and 0.23 [0.10–
0.38] for FTBI (p5NS). Median PFS were 26.3 (IC95%:13.6 –
47.3) and 13.1 (IC95%:7.4 – 25.6)months (mths) in FBA andFTBI re-
spectively.More relapses/progressions occurred in FTBI (p5 .005): 5
year relapse/progression CI of 0.28 [0.16– 0.40] (FBA) and 0.50 [0.39–
0.60] (FTBI). 3 pts died from secondary cancers (FBA: 1; FTBI: 2) and
38 fromTRMwith a 5 year TRMCI of 0.37 [0.25– 0.49] for FBA and
0.24 [0.14– 0.34] for FTBI (p5 0.199). FBA had a stronger negative
impact on patients’ QOL up to 80 days and resolved (EORTC
QLQ-C30 questionnaire). Evaluation of medical direct costs demon-
strated a crude advantage for FTBI (66,711V vs 42,080V for the
FBA and FTBI respectively, p\0.001). The cost-effectiveness ratio
using PFS as endpoint was 22,392 V per year of life free of relapse
gained using FBA conditioning regimen when compared to FTBI. In
conclusion, these 2 regimens produce similar 1 year OS. However,
FBA is associated with better 1 year PFS and socially acceptable cost-
effectiveness ratio but worse early QOL. FBA is also associated with
better long termdisease control, whereas FTBI tends toproduce lower
TRM and higher rejection rates.9
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TNF Receptor 1 (TNFR1) levels have previously been shown to
predict GVHD, non-relapse mortality (NRM) and overall survival.
We therefore conducted a phase II trial at two centers between
2005 and 2009 using the TNF-inhibitor etanercept together
with standard tacrolimus/methotrexate in high-risk allogeneic
matched unrelated donor (URD) (n5 68), single antigen mis-
matched URD (n5 25), or single antigen mismatched related donor
(n5 3) hematopoietic cell transplant (HCT) recipients. The median
age was 45y (range 2-61y). Patients received etanercept (0.4 mg/kg,
max 25 mg) twice weekly from the start of conditioning to day 56
in addition to tacrolimus and methotrexate (5 mg/m2 on days 1, 3,
6, and 11). The myeloablative conditioning regimens included flu-
darabine and IV busulfan 12.8 mg/kg (FluBu4, n5 31), BCNU/eto-
poside/cyclophosphamide or busulfan/cyclophosphamide (BCNU/
Busulfan, n5 36), and TBI/cyclophosphamide (TBI, n5 29).
We hypothesized that the administration of the TNF-inhibitor
etanercept would lower TNFR1 levels, and thereby protect
against GVHD and NRM while improving survival. The median
day 7 TNFR1 level was 2518 pg/mL in study patients, signifi-
cantly lower than the 3529 pg/mL seen in 132 control patients
(p\0.001) matched for age, conditioning regimen, degree of
HLA-match, and disease status. We then examined whether day
7 TNFR1 levels were associated with outcomes in study patients
and found an increased risk for NRM (HR 2.0, p\0.001) and
death (HR 1.5, p\0.06) for each doubling of TNFR1 levels.
As shown in the Table, the day 7 TNFR1 levels differed statisti-
cally according to the myeloablative conditioning regimen
(p\0.001). FluBu4 patients experienced the lowest day 7
TNFR1 levels compared to other study patients and had the low-
est rates of grade 2-4 GVHD (39% p5 0.04), no deaths in theS157
